To compare the safety of obinutuzumab by: 5. Comparing how well obinutuzumab versus rituximab in treating the disease. 6. Comparing the
by T Berger 2024Introduction - The recent GALLIUM study showed an advantage of 7% in progression free survival in favor of obinutuzumab (G) vs. rituximab
Obinutuzumab is different/superior to rituximab (chimeric) ofatumumab KidneyWk.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody (mAb), recognizing a unique CD20 extracellular membrane epitope with enhanced antibody dependent cellular cytotoxicity (ADCC) vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL.
Our analysis shows that O-chemo was more costly ( 40,477 for obinutuzumab vs 25,503 for rituximab) but more effective, with expected OS prolongation of 0.97 years (14.31 LYs for obinutuzumab vs 13.35 for rituximab). This corresponds to a 0.88 QALY gain (12.55 QALYs for obinutuzumab vs 11.68 QALYs for rituximab).
Obinutuzumab in combination with bendamustine for treating rituximab rituximab, often followed by maintenance therapy with rituximab. However
alemtuzumab; chlorambucil plus rituximab; ibrutinib plus obinutuzumab rituximab with the steroid prednisone. Chemotherapy drugs
Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are